Traws Pharma Provides Regulatory Update on Influenza Program
Traws Pharma announced the deferment of its planned Phase 2a human influenza challenge study for its lead antiviral candidate, tivoxavir marboxil (TXM), due to a negative review by the UK's MHRA. Despite the setback, the company remains committed to advancing TXM and other back-up influenza antiviral compounds with improved profiles, highlighting t…